Dermira, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies to treat dermatologic diseases. The company's product candidates include Glycopyrronium tosylate, a novel form of an anticholinergic agent that has completed Phase III clinical trial for the treatment of primary axillary hyperhidrosis; Olumacostat glasaretil, a novel small molecule designed to target sebum production, which is in Phase III clinical trial for the treatment of acne vulgaris; and lebrikizumab, a novel humanized monoclonal antibody targeting interleukin 13 that is in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. It has licensing agreements with Maruho Co., Ltd. to develop and commercialize glycopyrronium tosylate in Japan; and F. Hoffmann-La Roche Ltd and Genentech, Inc. to develop and commercialize lebrikizumab. The company was formerly known as Skintelligence, Inc. and changed its name to Dermira, Inc. in September 2011. Dermira, Inc. was founded in 2010 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-421-7200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.34 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
Dermira (NASDAQ:DERM) Frequently Asked Questions
What is Dermira's stock symbol?
Dermira trades on the NASDAQ under the ticker symbol "DERM."
How were Dermira's earnings last quarter?
Dermira Inc (NASDAQ:DERM) posted its quarterly earnings data on Tuesday, February, 26th. The biopharmaceutical company reported ($1.70) EPS for the quarter, beating the Zacks' consensus estimate of ($1.75) by $0.05. Dermira had a negative net margin of 523.25% and a negative return on equity of 309.23%. View Dermira's Earnings History.
When is Dermira's next earnings date?
What price target have analysts set for DERM?
9 brokers have issued 12 month price objectives for Dermira's stock. Their forecasts range from $6.71 to $20.00. On average, they anticipate Dermira's stock price to reach $15.7138 in the next year. This suggests a possible upside of 11.8% from the stock's current price. View Analyst Price Targets for Dermira.
What is the consensus analysts' recommendation for Dermira?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dermira.
What are Wall Street analysts saying about Dermira stock?
Here are some recent quotes from research analysts about Dermira stock:
- 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (3/4/2019)
- 2. HC Wainwright analysts commented, "Valuation Our $13 price target for Dermira is based on our sum of the parts NPV valuation based on the company’s two primary development programs, Qbrexza and lebrikizumab. Our DCF model utilizes a discount rate of 9.9%, which is based on the company’s equity cost of capital of 9.9% (Beta of 1.0, equity risk premium of 6.7%)." (2/14/2019)
Has Dermira been receiving favorable news coverage?
News headlines about DERM stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dermira earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
Who are some of Dermira's key competitors?
Some companies that are related to Dermira include Nabriva Therapeutics (NBRV), Ironwood Pharmaceuticals (IRWD), Enanta Pharmaceuticals (ENTA), AnaptysBio (ANAB), Supernus Pharmaceuticals (SUPN), Endocyte (ECYT), The Medicines (MDCO), Mallinckrodt (MNK), Endo International (ENDP), Heron Therapeutics (HRTX), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Xencor (XNCR), Allakos (ALLK) and Pacira Pharmaceuticals (PCRX).
What other stocks do shareholders of Dermira own?
Who are Dermira's key executives?
Dermira's management team includes the folowing people:
- Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 67)
- Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 77)
- Mr. Andrew L. Guggenhime, Chief Financial Officer (Age 51)
- Mr. Luis C. Peña, Chief Devel. Officer (Age 56)
- Ms. Lori Lyons-Williams, Chief Commercial Officer (Age 42)
Who are Dermira's major shareholders?
Dermira's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bank of America Corp DE (5.16%), Dimensional Fund Advisors LP (2.24%), Dimensional Fund Advisors LP (2.24%), Sofinnova Investments Inc. (1.29%), Millennium Management LLC (1.27%) and First Midwest Bank Trust Division (1.05%). Company insiders that own Dermira stock include Christopher M Griffith, David E Cohen, Eugene A Bauer, Fred B Craves, Matthew K Fust, Thomas G Wiggans and William R Ringo. View Institutional Ownership Trends for Dermira.
Which institutional investors are selling Dermira stock?
DERM stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP, Two Sigma Advisers LP, Tekla Capital Management LLC, Fosun International Ltd, Opaleye Management Inc., Northern Trust Corp and MetLife Investment Advisors LLC. View Insider Buying and Selling for Dermira.
Which institutional investors are buying Dermira stock?
DERM stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, First Midwest Bank Trust Division, Premier Asset Management LLC, Chicago Equity Partners LLC, Squarepoint Ops LLC, Sofinnova Investments Inc., Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. Company insiders that have bought Dermira stock in the last two years include Fred B Craves and Thomas G Wiggans. View Insider Buying and Selling for Dermira.
How do I buy shares of Dermira?
Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dermira's stock price today?
One share of DERM stock can currently be purchased for approximately $14.06.
How big of a company is Dermira?
Dermira has a market capitalization of $592.21 million and generates $42.34 million in revenue each year. The biopharmaceutical company earns $-221,540,000.00 in net income (profit) each year or ($5.24) on an earnings per share basis.
What is Dermira's official website?
How can I contact Dermira?
Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]
MarketBeat Community Rating for Dermira (NASDAQ DERM)
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe DERM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days.
